Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a diabetes drug help people stop using cannabis?

NCT ID NCT07468552

Disease control Sponsor: National Institute on Drug Abuse (NIDA) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 21, 2026 · Updated 1 time

Summary

This study tests a medicine called tirzepatide to see if it can help people with moderate to severe cannabis use disorder use less cannabis or stop altogether. One hundred adults aged 18 to 70 will receive either the drug or a placebo, and researchers will track their cannabis use and any side effects. The goal is to find a safe dose that helps reduce cravings and use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Between 18 and 70 years of age * Meets DSM-5 criteria for moderate or severe CUD * Interested in treatment for cannabis use disorder * Able to understand the study procedures and written informed consent in English * Willing to comply with all study procedures and medication instructions * If female, is not pregnant, and agrees to use acceptable birth control methods Exclusion Criteria: * Body Mass Index (BMI) ≤ 23 kg/m² * Presence of a medical or psychiatric disorder that contraindicates participation in the study * Substance use disorder other than tobacco or mild alcohol-use disorder * Known allergy or hypersensitivity to Tirzepatide, any GLP-1 or GIP receptor agonist, or any of the excipients in the product * Current or recent (past 30 days) use of GLP-1 receptor agonists or other weight-loss drug * Current or recent (past 6 months) enrollment in substance use disorder treatment * Current or planned pregnancy and breastfeeding * Living or medical situation that would interfere with adherence to the study protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cannabis use disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cannabis dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cannabis use disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.